Abstract: The present document describes a monolithic tablet dosage form for delivery of an active ingredient at two different release rates comprising a carboxyl polymer complexed with a multivalent cation and a disintegrating agent for a first initial fast release of the active ingredient, and a modulating agent for a second sustained release of the active ingredient. Also described are processes for preparing the carboxyl polymer complexed with a multivalent cation, and carboxyl polymer made from the process.

Abstract: The present document describes a monolithic tablet dosage form for delivery of an active ingredient at two different release rates comprising a carboxyl polymer complexed with a multivalent cation and a disintegrating agent for a first initial fast release of the active ingredient, and a modulating agent for a second sustained release of the active ingredient. Also described are processes for preparing the carboxyl polymer complexed with a multivalent cation, and carboxyl polymer made from the process.

Abstract: The present disclosure relates to a controlled release complex of a carboxylated polymer having carboxyl groups having a degree of substitution of about 0.1 to about 1.0, forming a complex through ionic interaction with an antimalarial alkaloid extract; a solid oral dosage form comprising the same, and a solid oral dosage form comprising an antimalarial drug combination which comprises the controlled release complex of the present invention and an antimalarial drug.

Abstract: The present document describes a dosage form for delivery of an active ingredient comprising: a first carboxylated polymer having carboxyl groups, having a degree of substitution of at least 0.2, a molecular weight of at least 200 kDa, and at least 30% of said carboxyl groups being complexed with a divalent cation; alone or in a co-complex with at least one of a) a control release polymer chosen from an insoluble polymer or a polymer having a reduced water solubility at 30° C., and a soluble polymer; and b) a second carboxylated polymer having carboxyl groups complexed with a divalent cation. The document also describes processes of making a carboxylated polymer having carboxyl groups, having a degree of substitution of at least 0.2, a molecular weight of at least 200 kDa, and at least 30% of said carboxyl groups being complexed with a divalent cation, and an inclusion complex, a co-complex, or both comprising the same.

Abstract: The present document describes a monolithic tablet dosage form for delivery of an active ingredient at two different release rates comprising a carboxyl polymer complexed with a multivalent cation and a disintegrating agent for a first initial fast release of the active ingredient, and a modulating agent for a second sustained release of the active ingredient. Also described are processes for preparing the carboxyl polymer complexed with a multivalent cation, and carboxyl polymer made from the process.

Abstract: The present document describes a dosage form for delivery of an active ingredient comprising: a first carboxylated polymer having carboxyl groups, having a degree of substitution of at least 0.2, a molecular weight of at least 200 kDa, and at least 30% of said carboxyl groups being complexed with a divalent cation; alone or in a co-complex with at least one of a) a control release polymer chosen from an insoluble polymer or a polymer having a reduced water solubility at 30° C., and a soluble polymer; and b) a second carboxylated polymer having carboxyl groups complexed with a divalent cation. The document also describes processes of making a carboxylated polymer having carboxyl groups, having a degree of substitution of at least 0.2, a molecular weight of at least 200 kDa, and at least 30% of said carboxyl groups being complexed with a divalent cation, and an inclusion complex, a co-complex, or both comprising the same.

Abstract: The present disclosure describes compositions for intestinal delivery of enzyme formulations and methods of treating health problems with these formulations. More specifically, the enzyme formulations include at least one histaminase and various methods of treatment of physical conditions, such as inflammation, allergy, histamine intolerance, and intestinal cancer.

Abstract: The present document describes a monolithic tablet dosage form for delivery of an active ingredient at two different release rates comprising a carboxyl polymer complexed with a multivalent cation and a disintegrating agent for a first initial fast release of the active ingredient, and a modulating agent for a second sustained release of the active ingredient. Also described are processes for preparing the carboxyl polymer complexed with a multivalent cation, and carboxyl polymer made from the process.

Abstract: The present document describes a powder composition comprising a functionalized starch having a single helix V-structure and having a degree of substitution of at least 0.25, and a bioactive agent, forming an inclusion complex with said functionalized starch, where the bioactive agent is within the helix V-structure of the functionalized starch having a single helix V-structure. Also described are the functionalized starch having a single helix V-structure and having a degree of substitution of at least 0.25, methods of making the same and methods of using the same to manufacture the powder composition.

Abstract: The present document describes a dosage form for delivery of an active ingredient comprising: a first carboxylated polymer having carboxyl groups, having a degree of substitution of at least 0.2, a molecular weight of at least 200 kDa, and at least 30% of said carboxyl groups being complexed with a divalent cation; alone or in a co-complex with at least one of a) a control release polymer chosen from an insoluble polymer or a polymer having a reduced water solubility at 30° C., and a soluble polymer; and b) a second carboxylated polymer having carboxyl groups complexed with a divalent cation. The document also describes processes of making a carboxylated polymer having carboxyl groups, having a degree of substitution of at least 0.2, a molecular weight of at least 200 kDa, and at least 30% of said carboxyl groups being complexed with a divalent cation, and an inclusion complex, a co-complex, or both comprising the same.

Abstract: The present document describes a composition for sustained, targeted or sustained and targeted delivery of an active ingredient which includes a complex formed between a carboxyl substituted polymer and a lipid. The present document also describes dosage forms containing the composition, and an active ingredient, and methods of using the same for the treatment of diseases.

Abstract: The present document describes a composition for sustained, targeted or sustained and targeted delivery of an active ingredient which includes a complex formed between a carboxyl substituted polymer and a lipid. The present document also describes dosage forms containing the composition, and an active ingredient, and methods of using the same for the treatment of diseases.

Abstract: The present disclosure describes compositions for intestinal delivery of enzyme formulations and methods of treating health problems with these formulations. More specifically, the enzyme formulations include at least one histaminase and various methods of treatment of physical conditions, such as inflammation, allergy, histamine intolerance, and intestinal cancer.

Abstract: The present document describes a method of treating a histamine-mediated condition by administering an effective amount of a histaminase of vegetable origin to a subject in need. The histamine-mediated condition may be an allergic shock, septic shock, allergic asthma, anaphylaxis, rhinitis, allergic conjunctivitis, urticaria, atopic dermatitis, and pruritus.

Abstract: A carboxymethyl starch and chitosan polyelectrolyte complex is provided. A carrier comprising this polyelectrolyte complex along with a solid oral dosage form comprising this polyelectrolyte complex are also provided. A method of manufacturing the polyelectrolyte complex is also provided.

Abstract: The present document describes a monolithic tablet dosage form for delivery of an active ingredient at two different release rates comprising a carboxyl polymer complexed with a multivalent cation and a disintegrating agent for a first initial fast release of the active ingredient, and a modulating agent for a second sustained release of the active ingredient. Also described are processes for preparing the carboxyl polymer complexed with a multivalent cation, and carboxyl polymer made from the process.

Abstract: Compositions for the selective delivery of an agent comprising an uncrosslinked starch modified by an acidic group and an agent are described. The compositions are substantially resistant to degradation and thus result in no or substantially no release of the agent in a first environment, and are capable of degradation in a second environment thereby allowing release of the agent. The pKa of the acidic group of the uncrosslinked starch used is higher than the pH of the first environment and lower than or equal to the pH of the subsequent environment. Also described herein are methods of preparing the compositions, methods of using the compositions and the uncrosslinked starch modified by an acidic group, and corresponding commercial packages.

Abstract: A histaminase of vegetable origin to be used in the treatment of allergic and septic shock and in allergic asthma, and the preparation of the histaminase for pharmaceutical use and the corresponding pharmaceutical compositions.

Abstract: The invention discloses a biocompatible polymeric matrix which is functionalized through the reaction with a functionalizing agent including protonated carboxylic acid groups. There is also disclosed a method of preparation of the polymeric matrix and a pharmaceutical composition including the matrix as a carrier for controlled release of a bioactive agent. The pharmaceutical composition is suitable for immobilizing and protecting the bioactive agent from denaturing factors, and can take various forms such as tablets, spheres, films, hydrogels, and emulsions.

Abstract: A neuroprotective composition for protecting neuronal cells against oxidative stress and methods for using and preparing the same. More particularly, the neuroprotective composition of the invention comprises a mixture of pyruvate, antioxidant, and lipid(s) such as fatty acids. The neuroprotective composition could be used for the treatment of brain trauma, brain or cerebrovascular ischemia, neurodegenerative diseases, poisoning of neuronal cells, the diminution of drugs side effects and for preservation of neuronal grafts.